CMS Targets Medicare Advantage Directory Accuracy and PBM Payment Structure
CMS is moving toward a more public-facing approach to two persistent pressure points in drug and coverage administration: Medicare Advantage provider directories and pharmacy benefit manager payment practices. The proposal would make directory performance visible to consumers and would also place flat-fee limits on PBM compensation, a step aimed at reining in arrangements that have long been criticized for obscuring how money flows through the pharmacy channel.
The two ideas sit in different parts of the healthcare system, but they share the same policy logic. Patients depend on accurate provider directories to find in-network clinicians without delay, while employers and health plans depend on transparent PBM pricing to understand what they are actually paying for prescription management. In both cases, the absence of clear information can create administrative friction, delayed care, and unnecessary cost. A public score for directory performance would turn a back-office function into a measurable quality signal. Flat-fee limits would push PBM compensation away from opaque percentage-based or spread-driven structures and toward a more legible payment model.
Directory accuracy has become more than a clerical concern. When a beneficiary relies on a Medicare Advantage directory that lists a clinician who is no longer in network, unavailable, or misclassified, the consequence is often a broken referral path and a frustrated patient who may delay care or pay out of pocket. For older adults navigating multiple conditions, even a small error can ripple through primary care follow-up, specialist access, and medication management. Public scoring would introduce reputational pressure on plans to keep those lists current, which could tighten oversight around one of the most visible front doors into managed care.
The move also reflects a broader federal interest in making managed-care performance easier to compare. A directory score can function as a consumer protection tool only if the underlying methodology is strict enough to distinguish between plans that maintain current listings and those that let directory data drift. Even without the technical details of the metric, the policy direction is obvious: plans would be judged not just on premiums or supplemental benefits, but on whether their network information is reliable in everyday use.
PBM reform carries its own clinical and financial stakes. Prescription access depends on the administrative machinery that determines formulary placement, rebate flows, dispensing fees, and network terms. When PBM compensation is tied to complex pricing mechanics, purchasers often struggle to determine how much of a drug’s cost reflects clinical value, administrative service, or opaque margin. Flat-fee limits would simplify one part of that equation by constraining how PBMs are paid for their role in managing pharmacy benefits.
Such a change could alter incentives across the medication supply chain. A fixed-fee model may reduce the appeal of arrangements that reward higher list prices or hidden spreads, and it could make contract comparisons easier for plans and purchasers. It would not, by itself, settle broader disputes over drug prices, formularies, or rebate pass-through, but it would narrow the room for pricing structures that are difficult for regulators and buyers to scrutinize. For patients, the downstream effect could be less volatility in cost-sharing and fewer distortions in how medications are steered through the benefit design.
The policy pairing is telling. One proposal tries to make provider access more visible to the public; the other tries to make pharmacy payment more transparent to buyers and regulators. Both are responses to sectors where information asymmetry has favored the entity holding the contract rather than the patient trying to use it. In Medicare Advantage, that asymmetry often appears at the point of care selection. In PBM contracting, it appears deep in the prescription reimbursement chain, where patients rarely see the structures shaping their copays and access.
For hospitals and clinicians, directory accuracy has practical implications that extend beyond patient inconvenience. Network confusion can increase scheduling delays, produce avoidable administrative churn, and send patients back into the system after failed referral attempts. A public score would likely intensify pressure on plans to keep physician affiliations, practice locations, and participation status current. The real-world test will be whether those scores are tied to meaningful enforcement and not merely to another layer of reporting that plans can satisfy on paper while leaving users with stale information.
PBM flat-fee limits raise a different set of operational questions. Any change to fee structure will affect contracting strategies among plans, pharmacies, and benefit administrators. It may also influence how aggressively PBMs compete on service features versus pricing mechanics. If the fee ceiling is set too loosely, it may not meaningfully change behavior. If it is set too tightly, some purchasers could worry about shifting costs elsewhere in the contract. Those details will determine whether the policy reduces opacity or simply moves it to a different line item.
Still, the direction of travel is clear enough. CMS is pressing on two areas where beneficiaries and purchasers have long lacked clean visibility into how managed care and pharmacy administration work in practice. One proposal would let the public see which Medicare Advantage plans maintain usable provider directories. The other would limit the degree to which PBMs can rely on flat-fee arrangements that may be easier to audit but harder to structure without disrupting existing contracts.
What comes next will depend on the final language, the enforcement mechanism, and how CMS chooses to define compliance. The headline policy intent is straightforward; the operational details will decide whether the proposals change behavior in a meaningful way or simply add a new reporting layer to an already crowded regulatory environment.